Key Highlights
- Third-quarter 2026 net loss was USD 11.3 million, or USD 0.21 per share.
- Research and development expenses were USD 9.2 million, against USD 6.4 million.
- General and administrative expenses were USD 2.4 million, against USD 2.6 million.
- Cash, equivalents and marketable securities totaled USD 34.9 million as of September 30, 2026.
DiaMedica Therapeutics (NASDAQ:DMAC) reported a net loss of USD 11.3 million, or USD 0.21 per share, for the third quarter ended September 30, 2026, in line with an estimate of a loss of USD 0.21 per share. The clinical-stage biopharmaceutical company, which reported no revenue, is developing DM199 for acute ischemic stroke and for preeclampsia and fetal growth restriction.
Quarterly Financial Results
Research and development expenses were USD 9.2 million, against USD 6.4 million in the third quarter of 2025. General and administrative expenses were USD 2.4 million, against USD 2.6 million. Operating loss was USD 11.6 million, against USD 9.0 million, and other income, net, was USD 0.3 million, against USD 0.4 million.
Share-based compensation was USD 1.5 million in the quarter, against USD 1.0 million. Operating expenses excluding share-based compensation were USD 10.1 million, against USD 8.0 million, a non-GAAP presentation in the filing. Net loss was USD 11.3 million, against USD 9.1 million in the same quarter of 2025 on an operating loss of USD 9.0 million and other income of USD 0.4 million. The company reported shareholders' Equity of USD 28.7 million and total accrued liabilities of USD 4.7 million as of September 30, 2026, against USD 3.5 million at year-end. Compensation accruals were USD 1.5 million, and professional services fees were USD 171 thousand. Research and Development services accruals were USD 168 thousand, against USD 749 thousand at year-end.
Nine-Month Results
For the nine months ended September 30, 2026, research and development expenses increased to USD 25.4 million from USD 17.9 million, while general and administrative expenses were USD 7.2 million, against USD 7.3 million. Operating loss was USD 32.6 million, against USD 25.2 million, and other income, net, was USD 1.1 million, against USD 1.2 million.
As of September 30, 2026, the company had incurred losses of USD 204.3 million since its inception in 2000. Accrued liabilities included USD 2.8 million of clinical trial costs, against USD 1.3 million at December 31, 2025.
Liquidity and Clinical Programs
The company had combined cash, cash equivalents and marketable securities of USD 34.9 million, Working Capital of USD 28.0 million and shareholders' equity of USD 28.7 million as of September 30, 2026. The filing states that operating losses are projected to increase moderately as the company continues research, development and clinical studies of DM199, including expansion of its preeclampsia clinical development program and continuation and global expansion of its ReMEDy2 trial.
The filing describes a Phase 2, proof-of-concept investigator-sponsored trial of DM199 for preeclampsia and fetal growth restriction, and the Phase 2/3 ReMEDy2 trial for acute ischemic stroke. It states that site activations and enrollment in ReMEDy2 have been slower than the company had planned, which the company believes is due in part to hospital staffing shortages, protocol inclusion and exclusion criteria and other factors. It also notes that additional financing may be required and that equity or convertible Debt Financing could dilute shareholders.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...